FINWIRES · TerminalLIVE
FINWIRES

野島建設、日立製作所の家電事業の株式80.1%を1100億円で取得へ

-- 野島電機(東証:7419)は、日立製作所(東証:6501)の家電事業を吸収合併する新会社に80.1%出資することで合意した。買収総額は1,101億円。これは火曜日に東京証券取引所に提出された書類で明らかになった。 日立グローバルライフソリューションズ(日立GLS)の買収は、野島電機の完全子会社である特別目的会社(SPC)を通じて行われる。 合意に基づき、日立GLSは吸収合併方式による会社分割で家電事業を新会社に移管し、野島電機のSPCが過半数株式を取得する。 同時に、日立GLSはアルチェリク日立ホームアプライアンス(AHHA)の残りの60%株式をアルチェリクから取得し、新会社がAHHAを完全子会社化することで、日立の家電事業をグローバルに統合する。 野島製作所は、顧客エンゲージメントにおける強みと日立製作所の製造ノウハウを融合させ、高付加価値製品を提供するとともに、グローバルに統合されたビジネスモデルの構築を目指します。 株式取得は、2027年3月期中に完了する予定です。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF